Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects

By  

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 2, 2016-03 ,pp. : 150-161

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 188-195

John Wiley & Sons Inc

Access to resources Recommend Favorite

Absence of Clinically Relevant Interactions between Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects

By Kubitza D   Becka M   Roth A   Mueck W  

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1688-1707

Field House Publishing

Access to resources Recommend Favorite

The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects

By Ding Yi   Jia YanYan   Song Ying   Lu ChengTao   Li YuWen   Chen MinChun   Wang MingMing   Wen AiDong  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 2, 2014-02 ,pp. : 141-146

Springer Publishing Company

Access to resources Recommend Favorite

The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

By Kadokura Takeshi   Adel Martin   Krauwinkel Walter   Takeshige Tetsuo   Nishida Akito  

European Journal of Clinical Pharmacology, Vol. 64, Iss. 6, 2008-06 ,pp. : 605-609

Springer Publishing Company

Access to resources Recommend Favorite